Multi-dose Wegovy FlexTouch pen reported to be rolling out in the US
A trade newsletter says Novo Nordisk is readying a US launch of a reusable, four-dose Wegovy pen for the 2.4 mg maintenance dose, and FDA records already list the device, though Novo Nordisk has not confirmed a launch date.
A GLP-1 industry newsletter, On The Pen, reported on August 8, 2026, that multiple unnamed sources told the publication Novo Nordisk is preparing to launch a multi-dose Wegovy FlexTouch pen in the United States "in the coming weeks" [1]. As of September 2026, Novo Nordisk had not issued its own press release announcing a launch [1].
Today, most US Wegovy injections come in single-dose pens: one pen delivers one weekly 2.4 mg shot, and the whole device is thrown away after use [1]. The FlexTouch device described in the report works differently. According to the FDA-approved Wegovy prescribing information, a FlexTouch presentation contains 9.6 mg of semaglutide in 3 mL and is built to deliver four separate weekly 2.4 mg doses from a single pen, with a new disposable needle attached before each injection [2]. The newsletter notes this same reusable pen platform is already used for Novo Nordisk's Ozempic [1].
The prescribing information also shows the FDA has already reviewed safety language specific to this device. A revision dated June 2026 added a new warning, "Never Share WEGOVY FlexTouch Between Patients," even if the needle is changed [2]. That addition is evidence the multi-dose pen has cleared FDA review, separate from any commercial launch decision by Novo Nordisk.
The newsletter's sourcing indicates the launch would apply specifically to the 2.4 mg strength, which is the usual maintenance dose for most patients on Wegovy long-term, rather than the lower titration doses [1][2]. The single-dose pens and Wegovy tablets would remain part of the product lineup [2].
Why it matters for patients
If a multi-dose FlexTouch pen does reach US pharmacies, the practical difference for someone already at the 2.4 mg maintenance dose would mainly involve packaging and handling: one pen used across roughly four weekly injections, with needles changed each time, instead of four separate pens discarded after single use [1]. That could mean less refrigerator space used and less packaging waste for patients at that stage of treatment [1].
The newsletter also raises a question it has not confirmed: whether pricing or self-pay options might differ for the FlexTouch format compared with existing single-dose pens [1]. Nothing in the sources establishes how insurers, pharmacies, or Novo Nordisk's cash-pay programs would treat the new device, and Novo Nordisk has not addressed pricing publicly as of this report [1].
The newsletter's author speculates that a multi-dose pen could tempt some prescribers to write for the higher-dose device while directing patients on lower maintenance doses to use it more sparingly, which the author explicitly says "would go against the label and package insert" [1]. That is the newsletter's own characterization of a hypothetical off-label use, not a confirmed practice, and it is not something described in the FDA prescribing information [2].
What happens next
As of the report, no official Novo Nordisk launch announcement, launch date, or pricing details had been published [1]. The FDA prescribing information reflects the FlexTouch device as an approved dosage form as of the June 2026 label revision [2], but confirmation of when it will appear in US pharmacies, and under what pricing, depends on a formal announcement from Novo Nordisk, which had not occurred as of September 2026 [1].
Images from the sources
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.